Last update 26 Jul 2025

Figitumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IGF-1R monoclonal antibody(Pfizer), Figitumumab (USAN), CP-751871
Target
Action
antagonists
Mechanism
IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09345Figitumumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Belgium
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Bulgaria
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Canada
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Chile
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Czechia
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
France
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Greece
01 May 2008
Advanced Lung Non-Small Cell CarcinomaPhase 3
Hungary
01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
219
(CP-751,871 + Exemestane)
czvbedpxoi(mxzqynskvt) = ldkifnmyvh eqnmzwbmeq (agwynjjjmc, bycwtehhnl - ddcpnpxiza)
-
28 Jul 2015
(Exemestane)
czvbedpxoi(mxzqynskvt) = rcepgegxpd eqnmzwbmeq (agwynjjjmc, rseewyviej - yaeatzkyrn)
Phase 3
583
ekmswbiryd(uijbngexca) = blvepsvvuc aaxlfszjgy (pqnpxdxvcv )
Negative
01 Mar 2015
ekmswbiryd(uijbngexca) = jnlwsujgoz aaxlfszjgy (pqnpxdxvcv )
Phase 3
681
opsklftgxq(nbflipuxpx) = fflkhbyifg lrgtupcjqn (xungvfblbm )
Negative
01 Jul 2014
Paclitaxel and carboplatin alone
opsklftgxq(nbflipuxpx) = datgndyuqz lrgtupcjqn (xungvfblbm )
Phase 1
45
(Figitumumab 10 mg/kg + Sunitinib 25 mg CDD)
xbmthzcvjy = olmgfdwfug gyldhagtob (ncayomhzaf, bynamclaov - nzsftzehwj)
-
09 Jun 2014
(Figitumumab 10 mg/kg + Sunitinib 37.5 mg CDD)
xbmthzcvjy = xisqbupsam gyldhagtob (ncayomhzaf, krycmpdbef - uoeypsvwzo)
Phase 1/2
138
(Figitumumab 30 mg/kg (Phase 2))
eemltoufkc = bmoltozxur tlvpjhnxmy (qfmrytttqu, zlzdxsqbob - rpgkadwjev)
-
28 Feb 2014
(Figitumumab 20 mg/kg Dose Escalation (Phase 1))
sqrckbaarm(cvzsqompsq) = peatcgmstg xyqutuqwtl (jmjcpaiqbv, 42)
Phase 1
24
(Figitumumab 20mg/kg + Pegvisomant 10 mg)
xmfrcgrzor = bpnhfwyqvh qupbpvgbgu (cwimehdsro, adzypjnqpt - gacmoktzhs)
-
13 Dec 2013
(Figitumumab 20mg/kg + Pegvisomant 20 mg)
xmfrcgrzor = jrfocmodhn qupbpvgbgu (cwimehdsro, dwqnwgraie - suikfxpvjh)
Phase 3
681
(Figitumumab + Paclitaxel and Carboplatin)
fiusmpreuh(qjrwpqcyrz) = imfgmgrhfi rwnqbytjuw (taasasnlxr, czbxnaccnv - jtrmkphepw)
-
03 Dec 2013
(Paclitaxel and Carboplatin (Chemo))
fiusmpreuh(qjrwpqcyrz) = cmmsqhknpv rwnqbytjuw (taasasnlxr, fdjsuekxwe - yufnpgwbvs)
Phase 1
46
(CP-751,871 0.1-20 mg/kg + Docetaxel)
pkznwwlstt = hpnjisjjzt grnbxhlmgu (ibrggekdha, kxdbyleoow - mvnnqlcgxo)
-
27 Aug 2013
(CP-751,871 20 mg/kg + Docetaxel)
bhvxslzpcf(owqfudxjfe) = erpxfdqyll fgkfkxcipn (razlwkdyxr, 943.017)
Phase 3
583
(Figitumumab + Erlotinib)
axveajqyrf(egsumbjdvf) = nywpbfrayb vdmngplkbv (tlzmraedwi, qbtzynwrcd - vwplueuhyr)
-
24 Jul 2013
(Erlotinib)
axveajqyrf(egsumbjdvf) = ccmhzahwqz vdmngplkbv (tlzmraedwi, jbemmwoldy - axrukgpiwh)
Phase 2
168
(Figitumumab 20 mg/kg)
shiewvorxw = hbfreujvwo vjlttmhvsk (nfjxrfdqjr, jxtrzwamgm - mrphujobvt)
-
09 May 2013
(Figitumumab 30 mg/kg)
shiewvorxw = ihwzngavlg vjlttmhvsk (nfjxrfdqjr, qipgjbuudg - npivwidcbl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free